Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Sells 3,400,000 Shares

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. The trade was a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock traded up $0.06 during mid-day trading on Monday, reaching $1.95. The stock had a trading volume of 4,622,390 shares, compared to its average volume of 653,824. Aldeyra Therapeutics, Inc has a one year low of $1.14 and a one year high of $7.20. The company has a 50-day moving average price of $6.00 and a two-hundred day moving average price of $5.44. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.30). As a group, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

ALDX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday. BTIG Research cut their price target on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday.

Hedge Funds Weigh In On Aldeyra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $3,628,000. State Street Corp increased its holdings in Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after buying an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after buying an additional 295,864 shares during the last quarter. Barclays PLC lifted its stake in Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 48,313 shares during the period. Finally, SG Americas Securities LLC lifted its stake in Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 2,822 shares during the period. 59.71% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.